Health Care • Medicinal Chemicals and Botanical Products
$0.65 ▼ -0.02
(-3.33%)
MKT CAP: $285.6M • VOL: 2.28M
52W L $1 52W H $2
ROARABLE / RQD
D- • 41/100
PIOTROSKI
1 / 9
CGC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-03-31 | FY 2024
FILED 2025-03-31 | FY 2023
FILED 2024-03-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $0 | $0 | $0 |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$189.0M | -$354.0M | -$526.0M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | — | — | — |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | — | — | — |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | — | — | — |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | — | — | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CGC.